Chemotherapy with the use of next-generation TKIs based on MRD has the potential to avoid hematopoietic stem cell transplantation in treatment for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Mixue XieTing ShiQi JiangYunlu JiaDe ZhouHongyan TongJie JinHong Hu ZhuPublished in: Cancer (2023)
Our novel findings suggest that combination chemotherapy plus TKIs leads to a comparable survival benefit as with allo-HSCT for MRD-negative (CMR) patients. This study provides novel evidence for allo-HSCT indications for Ph+ ALL in CR1 in the TKI era.
Keyphrases
- acute lymphoblastic leukemia
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- locally advanced
- prognostic factors
- acute myeloid leukemia
- peritoneal dialysis
- advanced non small cell lung cancer
- gene expression
- chronic myeloid leukemia
- patient reported
- epidermal growth factor receptor